Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone.
- Trial name
- NCT00528879
- Testing
- Dapagliflozin, Metformin
- Where
- 75 sites in United States, Argentina and 3 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Type2 Diabetes
Data Acquisition Study in Inadequately Balanced Patients With Type 2 Diabetes Mellitus
The aim of this study is to collect continuous glucose monitoring (CGM) data, coupled with physical activity and everyday day life data.
- Trial name
- NCT04155996
- Testing
- data collection
- Where
- France
- Volunteers
- 10 people
- Sponsor
- ValoTec
Diabetes Mellitus, Type 2
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
The purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. Participants will get oral semaglutide as prescribed to them by the study doctor.
- Trial name
- PIONEER REAL (NCT05502562)
- Testing
- Oral semaglutide
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07691203
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to evaluate the safety and efficacy of alogliptin, once daily (QD), taken in combination with pioglitazone in adults with type 2 diabetes mellitus.
- Trial name
- NCT00328627
- Testing
- Alogliptin, Pioglitazone
- Where
- 90 sites in United States, Australia and 17 more
- Volunteers
- 1,554 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 2
A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump
This trial is conducted in the United States of America (USA). This is an in-patient trial investigating stepwise dose increase in a period of up to 3-weeks followed by a 10-week out-patient maintenance period.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00115973
- Testing
- pump, insulin aspart
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
The purpose of this clinical research study is to assess the safety of, exposure to, and biological effects of BMS-512148 in stable Type 2 diabetic subjects
- Trial name
- NCT00162305
- Testing
- BMS-512148
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background…
- Trial name
- RECORD (NCT00379769)
- Testing
- Rosiglitazone, Sulfonylurea, Metformin
- Where
- 446 sites in Australia, Belgium and 23 more
- Volunteers
- 4,447 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2, Diabetes Mellitus
A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes
The purpose of this study is to investigate the effectiveness and safety of 12 weeks of treatment with R256918 in patients with Type 2 Diabetes Mellitus who are taking metformin.
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases, Nutritional and Metabolic Diseases
- Trial name
- NCT00672386
- Testing
- JNJ16269110, Metformin, Dietary Counseling
- Where
- 62 sites in Belgium, Denmark and 9 more
- Volunteers
- 352 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects
This trial is conducted in Europe and Japan. The aim of this clinical trial is to investigate the possible difference in the development of type 2 diabetes in a Japanese and a Caucasian population.
- Trial name
- NCT00897169
- Testing
- Oral Glucose Tolerance Test (OGTT), Euglycaemic hyperinsulinaemic clamp
- Where
- 2 sites in Denmark, Japan
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.
- Trial name
- CWP-DIANA-302 (NCT01529541)
- Testing
- Anagliptin, Sitagliptin
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- JW Pharmaceutical
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.
- Trial name
- NCT01126580
- Testing
- Metformin, LY2189265
- Where
- 91 sites in United States, Argentina and 17 more
- Volunteers
- 807 people
- Sponsor
- Eli Lilly and Company
Diabetes type2, Obesity
The RESET System Pivotal Clinical Trial (Protocol Revision K)
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.
- Trial name
- STEP-1 (NCT04101669)
- Testing
- RESET Liner
- Where
- 27 sites in United States
- Volunteers
- 264 people
- Sponsor
- Morphic Medical Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.
- Trial name
- EUROMIX (NCT00619697)
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 54 sites in Austria, Czechia and 5 more
- Volunteers
- 260 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus in Obese, Obesity
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
- Trial name
- NCT05409027
- Testing
- SPI-62, Cortisone-d8
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sparrow Pharmaceuticals
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-F1 (NCT00763451)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c…
- Trial name
- NCT05297045
- Testing
- RGT001-075
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Regor Pharmaceuticals Inc.
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes
This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.
- Trial name
- NCT00427154
- Testing
- rosiglitazone, inhaled human insulin, metformin
- Where
- 103 sites in United States
- Volunteers
- 227 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of probiotics ADR-1/GMNL-263 capsules (Lactobacillus reuteri ADR-1/ Lactobacillus reuteri GMNL-263) for the treatment of adults with type2 DM.
- Trial name
- NCT02274272
- Testing
- ADR-1, GMNL-263
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- GenMont Biotech Incorporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.